HIV Treatment Bulletin - Vol. 5, No. 4, May 2004
Simon Collins, HIV i-Base

On 25 March, the US Food and Drug Administration (FDA) convened a panel to review study results for accelerated approval of New-Fill (Sculptra). The studies that were reviewed included the early Vega Study from Paris and the study from the Chelsea and Westminster Hospital in London. New-Fill is now owned by Aventis/Dermik. The meeting also included public testimony from patients on how lipoatrophy made it difficult to lead a normal life and that treatment had changed their personal and professional lives.

New-Fill is already used in the UK to repair HIV-related facial lipoatrophy, but until National Health Service programmes are established, access has been largely limited to patients who can pay privately for this treatment. Approval in the US is likely to encourage NHS acceptance of this treatment.

The FDA panel voted 9-0 to recommend that FDA grant conditional approval for correction of facial shape and contour deficiencies resulting from facial fat loss associated with HAART for HIV. This does not mean that New-Fill has been approved but it is very unusual for a panel recommendation not to be followed. As conditions of approval, the panel recommended FDA require a two to five year post market study. Further research should attempt to establish differences, if any, of New-Fill therapy on women, minorities and patients with normal immune systems. The panel also urged FDA to go beyond strong labeling warnings to prevent New-Fill from being used off label for non-HIV patients.

Significant weight was given to the personal testimonies at the meeting.

Data slide presentation:
http://www.fda.gov/ohrms/dockets/ac/04/slides/4031s1.htm

Further report:
http://www.natap.org/2004/HIV/032904_02.htm

040510
IB040504-17

©2004. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.